Your session is about to expire
← Back to Search
Plamotamab for Blood Cancers
Study Summary
This trial is testing a new drug to see if it is safe and how well it is tolerated. They will also determine the Maximum Tolerated Dose (MTD) or Recommended Dose (RD).
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't had chemotherapy, radiotherapy, or immunotherapy in the last 4 weeks.I have had brain lymphoma or cancer affecting my nervous system.I have been diagnosed with multiple myeloma, plasma cell leukemia, or B cell acute lymphoblastic leukemia.I am allergic or have had a bad reaction to CD20 monoclonal antibody therapy.My bilirubin levels are high, but it's due to a known condition.I have a seizure disorder.I haven't had serious infections in the last 30 days.I can take care of myself and am up and about more than half of the day.I am willing and able to participate in the whole study.I have been diagnosed with DLBCL or transformed low-grade lymphoma.My DLBCL has not responded to at least 2 treatments, including one with anti-CD20.I am not eligible for or am refusing stem cell transplant for my DLBCL.I have been diagnosed with follicular lymphoma Grades 1-3a.I have serious heart or lung problems.I have had a solid organ transplant.I still have severe side effects from my last treatment.I have an autoimmune disease that is not under control.My kidney function is reduced with a creatinine clearance below 40 mL/min.I have not had a stroke in the last 6 months.I have tested positive for hepatitis B but am either vaccinated, have no active infection, or am on preventive treatment.My condition has not improved with standard treatments or I have no other treatment options.I have tried 2 or more treatments for my Follicular Lymphoma without success.My diagnosis is a non-CLL B cell cancer.I have not received a live vaccine within 2 weeks before starting XmAb13676.
- Group 1: CLL/SLL (Group CLL) Part B
- Group 2: Non-CLL B Cell Malignancies (Group NHL) Part B
- Group 3: Non-CLL B Cell Malignancies (Group NHL) Part C / Expansion
- Group 4: Non-CLL B Cell Malignancies (Group NHL) Part D / Expansion
- Group 5: Non-CLL B Cell Malignancies (Group NHL) Part A
- Group 6: CLL/SLL (Group CLL) Part A
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many potential participants are being accepted for this clinical experiment?
"Indeed, the details listed on clinicaltrials.gov affirm that this medical experiment is actively recruiting participants. This trial was initially posted in October 2016 and last revised in October 2021; 160 individuals are required to be enrolled from 7 distinct centres."
What deleterious effects might XmAb13676 have on individuals?
"At this stage, only limited data exists to support the safety and efficacy of XmAb13676. Our team at Power has thus assigned it a score of 1 on our scale from 1-3."
Are there multiple clinical locations in the U.S. administering this research?
"The seven medical sites that are participating in this trial include the University of Michigan at Ann Arbor, Gabrail Cancer Center Research in Canton, and Mayo Clinic in Jacksonville. An additional 4 locations round out the list of enrolment centres."
Are there any available enrolment slots for this research endeavor?
"Affirmative. The trial, which was initially made available on October 1st 2016, is actively seeking participants; clinicaltrials.gov provides evidence to this effect. 160 individuals are required from 7 distinct medical centres."
Who else is applying?
What state do they live in?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Share this study with friends
Copy Link
Messenger